Plenty Of Room For More Obesity Drugs, Says Boehringer, As Survodutide Enters Phase III

 
• By Andrew McConaghie
Dawn over the Pharmalogical Research building at Biberach, Germany
Boehringer Ingelheim's R&D center in Biberach, Germany. • Source: Boehringer Ingelheim

More from Clinical Trials

More from R&D